Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

977
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
977

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Free IL-18 in NLRC4-associated autoinflammatory disease without macrophage activation syndrome.

Rheumatology (Oxford, England)·2026
Same author

Ten-year update on the European Association of Urology Robotic Section (ERUS) fellowship training for robot-assisted radical prostatectomy.

BJUI compass·2026
Same author

Development of the Transurethral Treatment Intermediate Skills Curriculum for TURP (Step 2P): A Cognitive Task Analysis and Delphi Consensus from the European School of Urology.

Journal of endourology·2026
Same author

Proficiency-based training and evidence-based methodology: a systematic review and meta-analysis.

BJU international·2026
Same author

Autoantigen identification in antinuclear antibody-positive usual interstitial pneumonia without known autoantibody through immunoprecipitation-mass spectrometry.

ERJ open research·2026
Same author

Diffuse splenic calcifications in systemic lupus erythematosus: a case-based review.

Rheumatology international·2026

Related Experiment Video

Updated: May 12, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.4K

Anti-TIF1-beta autoantibody-positive dermatomyositis: a case-based review.

Jean-Baptiste Vulsteke1,2,3, Petra De Haes4,5,6, Minoru Satoh7,8

  • 1University Hospitals Leuven, Rheumatology, Leuven, Belgium. jean-baptiste.vulsteke@uzleuven.be.

Rheumatology International
|April 30, 2025
PubMed
Summary

Dermatomyositis (DM) with only anti-TIF1β autoantibodies presents a distinct subtype. This condition shows typical skin issues, mild muscle involvement, and a 20% cancer association, warranting further study.

Keywords:
AutoantibodiesDermatomyositisIdiopathic inflammatory myopathyMyositis

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

723
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

35.5K

Related Experiment Videos

Last Updated: May 12, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.4K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

723
Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate
10:05

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

Published on: January 17, 2018

35.5K

Area of Science:

  • Rheumatology
  • Immunology
  • Oncology

Background:

  • Dermatomyositis (DM) is an idiopathic inflammatory myopathy.
  • Anti-TIF1β autoantibodies are associated with DM and cancer.
  • The clinical spectrum of anti-TIF1β-monospecific DM requires further elucidation.

Purpose of the Study:

  • To characterize the clinical features and cancer risk in patients with anti-TIF1β-monospecific DM.
  • To differentiate this subset from other DM phenotypes.

Main Methods:

  • Case report of anti-TIF1β-monospecific cancer-associated DM.
  • Systematic literature review of anti-TIF1β-monospecific DM cases using PubMed and Scopus.
  • Immunoprecipitation-mass spectrometry for autoantibody identification.

Main Results:

  • A case of anti-TIF1β-monospecific DM with renal cell cancer demonstrated typical cutaneous findings, mild myositis, and good treatment response.
  • Literature review identified 9 additional cases, revealing a homogeneous phenotype: typical cutaneous involvement, mild/absent myositis, and no interstitial lung disease.
  • Cancer was identified in 20% of the 10 reviewed cases (anti-TIF1β-monospecific DM).

Conclusions:

  • Anti-TIF1β-monospecific DM is a distinct subset of DM.
  • This subset is characterized by specific cutaneous and muscular involvement patterns.
  • A 20% cancer association suggests a potentially elevated cancer risk, necessitating further investigation through cohort studies.